IDYA Novinky na Forexe
IDEAYA Biosciences Q4 Results Misses Estimates
IDEAYA Biosciences, Inc. (IDYA), a precision medicine oncology company, announced net loss of $32.64 million or $0.52 per share, wider than $23.07 million or $0.50 per share in the prior-year quarter.
RTTNews
|
Pred 333 dňami
IDEAYA Biosciences Says FDA Clears IND For Pol Theta Helicase Development Candidate GSK101
Oncology company IDEAYA Biosciences, Inc. (IDYA) announced Monday the clearance of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for initiation of a GSK-sponsored Phase 1/2 clinical trial to evaluate GSK101 (IDE705) for the treatment of patients having tumors with BRCA or other homologous recombination (HR) mutations or homologous recombination deficiency (HRD).
RTTNews
|
Pred 516 dňami
IDEAYA Biosciences Appoints Darrin Beaupre As Chief Medical Officer
Oncology company IDEAYA Biosciences, Inc. (IDYA) announced that Darrin Beaupre has joined the company as its Chief Medical Officer, effective November 21, 2022.
RTTNews
|
Pred 782 dňami
